ALK receptor tyrosine kinase
ALK receptor tyrosine kinase
Overview
ALK receptor tyrosine kinase is a receptor tyrosine kinase encoded by the ALK gene and is best known in medicine as a clinically important oncogenic target in several cancers, especially ALK-rearranged non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma. In normal biology, ALK is a membrane-associated signaling protein, but in cancer it is most often relevant through gene rearrangements/fusions that lead to constitutive kinase activation and downstream proliferative and survival signaling.
Because ALK-driven tumors can be highly dependent on this signaling axis, ALK has become a major target for ALK-tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, and lorlatinib. These agents have transformed treatment of ALK-positive NSCLC, including disease with central nervous system involvement, but resistance remains a major clinical challenge. Recent research also continues to use ALK status as a diagnostic and stratification marker in other tumors, including inflammatory myofibroblastic tumor and anaplastic large cell lymphoma.
Focus of Latest Publications
Recent publications on ALK receptor tyrosine kinase have focused heavily on ALK-driven non-small cell lung cancer, particularly the use of ALK-targeted tyrosine kinase inhibitors and related resistance mechanisms. Several studies examined clinical and translational questions around alectinib, lorlatinib, gilteritinib, and entrectinib, including first-line treatment strategies, induction therapy in stage III disease, and approaches to overcome resistance to second-generation ALK inhibitors. One exploratory study also assessed immune-related gene expression profiling in ALK-rearranged NSCLC to better characterize the tumor microenvironment and its relationship to alectinib efficacy.
A recurring theme is therapeutic resistance and how it may be modulated. In ALK-rearranged NSCLC, gilteritinib was reported to inhibit H2228/Al cell growth, induce apoptosis, reduce ALK protein levels, and overcome alectinib resistance in vitro and in a nude mouse xenograft model. The proposed mechanism involved inhibition of PD-L1 and CD8 co-expression. Another study evaluated the effects of nicardipine on entrectinib metabolism in vitro and in rats, reflecting interest in drug–drug interactions involving a multi-target TKI that includes ALK among its targets. A cost-effectiveness analysis also compared lorlatinib with alectinib as first-line therapy for ALK-positive advanced NSCLC in Italy, highlighting the continuing clinical evaluation of ALK inhibitors beyond efficacy alone.
Beyond lung cancer, ALK was investigated in other disease contexts and as a molecular marker. In anaplastic large cell lymphoma affecting the oral cavity, ALK protein expression was reported in two of three cases, consistent with the role of ALK gene fusions in subclassification of this lymphoma. In Parkinson’s disease, lorlatinib was studied as an ALK-specific inhibitor in an MPTP mouse model and was found to improve motor function, attenuate dopaminergic neuronal loss, suppress ALK phosphorylation, and reduce microglial and astrocytic activation, proinflammatory cytokine expression, oxidative stress, and blood–brain barrier disruption. These findings suggested a role for ALK-mediated neuroinflammation in the model.
Additional work extended ALK targeting into drug development and preclinical oncology. A study on modular silicon-containing pharmacophores reported the identification of sila-protein degraders, including a SiD-conjugated ALK degrader that showed significant tumor-suppressive activity in an ALK-positive H3122 xenograft model. Another study of induction alectinib or crizotinib for stage III ALK-fusion NSCLC with 4-year follow-up addressed the role of ALK-targeted induction therapy in locally advanced disease. Together, these publications show ALK receptor tyrosine kinase being studied as a therapeutic target, resistance marker, and disease-associated biomolecule across oncology and neuroinflammation.